Published in Br J Dermatol on May 26, 2014
Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag (2016) 0.97
Night-time sedating H1 antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled study. Br J Dermatol (2014) 0.78
Advances in Understanding and Managing Chronic Urticaria. F1000Res (2016) 0.76
Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy (2017) 0.75
A 63-year-old man with chronic spontaneous urticaria. CMAJ (2015) 0.75
Aquagenic urticaria: diagnostic and management challenges. J Asthma Allergy (2016) 0.75
Knowledge and Attitude of Medical Resident Doctors Toward Antihistamines. Indian J Dermatol (2015) 0.75
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
The impact of chronic urticaria on the quality of life. Br J Dermatol (1997) 2.08
The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol (2010) 1.56
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy (2005) 1.51
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy (2007) 1.36
Consensus statement on the management of urticaria. Indian J Dermatol (2011) 1.04
Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol (2007) 1.02
Basic mechanisms of itch. Clin Exp Allergy (2011) 0.98
Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy (2012) 0.95
The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. J Allergy Clin Immunol (1984) 0.94
The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol (2000) 0.94
Cost effectiveness of levocetirizine in chronic idiopathic urticaria : a pooled analysis of two randomised controlled trials. Clin Drug Investig (2006) 0.92
Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritic skin diseases. Allergol Int (2010) 0.86
Individual differences in central nervous system response to antihistamines (H1-receptor antagonists). Ann Allergy Asthma Immunol (1995) 0.84
H(1)-antihistamines and urticaria: how can we predict the best drug for our patient? Clin Exp Allergy (2012) 0.83
Effects of nonsedative antihistamines on productivity of patients with pruritic skin diseases. Allergy (2009) 0.83
Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial. J Clin Pharmacol (1998) 0.82
Levocetirizine: from scientific evidence to a potent modern-day treatment of today's allergic patients. Drugs Today (Barc) (2009) 0.81
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
Role of nonallergic hypersensitivity reactions in children with chronic urticaria. Allergy (1998) 3.20
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res (1993) 2.22
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy (2004) 2.13
Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy (2011) 2.13
Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med (1996) 1.97
Detecting SNPs using a synthetic nanopore. Nano Lett (2007) 1.73
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72
A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. Allergy (2008) 1.66
Human skin mast cells: their dispersion, purification, and secretory characterization. J Immunol (1987) 1.58
Beyond the Gene Chip. Bell Labs Tech J (2005) 1.57
Insulin allergy: clinical manifestations and management strategies. Allergy (2008) 1.56
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
Proceedings: The inhibitory effect of insulin on pinnal anaphylaxis in the mouse. Br J Pharmacol (1974) 1.54
Mast cells. Int J Dermatol (1995) 1.52
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51
Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy (2009) 1.49
Allergen extract-induced interleukin-10 in human memory B cells inhibits immunoglobulin E production. Clin Exp Allergy (2009) 1.47
Food allergy and non-allergic food hypersensitivity in children and adolescents. Clin Exp Allergy (2004) 1.45
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45
Characterization of histamine secretion from mechanically dispersed human lung mast cells: effects of anti-IgE, calcium ionophore A23187, compound 48/80, and basic polypeptides. J Immunol (1982) 1.45
Histamine release upon adenosine 5'-monophosphate (AMP) nasal provocation in allergic subjects. Thorax (1999) 1.43
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
Immunoglobulin E decapeptide-induced 5-hydroxytryptamine release from rat peritoneal mast cells. Comparison with corticotropin-(1-24)-peptide, polyarginine, polylysine and antigen. Biochem J (1981) 1.41
H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy (2002) 1.41
Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol (1984) 1.38
Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy (1992) 1.32
Adenosine inhibits and potentiates IgE-dependent histamine release from human basophils by an A2-receptor mediated mechanism. Br J Pharmacol (1983) 1.29
The inhibition by dexamethasone and disodium cromoglycate of anaphylactic bronchoconstriction in the rat. Br J Pharmacol (1972) 1.27
Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J Allergy Clin Immunol (1988) 1.27
Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol (1994) 1.27
Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis (1985) 1.25
Stretching and unzipping nucleic acid hairpins using a synthetic nanopore. Nucleic Acids Res (2008) 1.25
Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. Allergy (2005) 1.25
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol (1987) 1.24
Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. I. The association of disordered airway physiology to leukocyte infiltration. Am Rev Respir Dis (1988) 1.24
Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol (1980) 1.23
Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy (2011) 1.22
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy (2009) 1.22
Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy (1995) 1.21
Nanoelectromechanics of methylated DNA in a synthetic nanopore. Biophys J (2009) 1.20
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J Pathol (1990) 1.17
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy (2007) 1.16
Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol (1985) (1989) 1.16
Heterogeneity of human mast cells based on cytokine content. J Immunol (1995) 1.15
The relationship between cyclic AMP changes and histamine release from basophil-rich human leucocytes. Biochem Pharmacol (1983) 1.12
Human mast cells express stem cell factor. J Pathol (1998) 1.12
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy (2009) 1.11
Response of rat lung to humoral mediators of anaphylaxis and its modification by drugs and sensitization. Br J Pharmacol (1975) 1.10
Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am J Respir Crit Care Med (1997) 1.10
Adenosine potentiates immunological histamine release from rat mast cells by a novel cyclic AMP-independent cell-surface action. Br J Pharmacol (1985) 1.10
Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09
Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy (2009) 1.08
IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J Immunol (1995) 1.08
Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells. Br J Pharmacol (1986) 1.07
Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med (1995) 1.07
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07
Non-IgE-dependent bacteria-induced histamine release from human lung and tonsillar mast cells. Clin Allergy (1987) 1.06
Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol (2008) 1.06
ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy (2008) 1.05
Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy (2014) 1.05
Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig Dis Sci (1990) 1.04
The neurogenic vasodilator response to endothelin-1: a study in human skin in vivo. Exp Physiol (2000) 1.04
Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04
GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy (2009) 1.03
Role of eosinophil activation in the bronchial reactivity of allergic guinea pigs. Am J Respir Crit Care Med (1994) 1.03
Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study. Clin Exp Allergy (1997) 1.02
9 alpha,11 beta-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways. J Clin Invest (1987) 1.02
The response of plasma histamine to bronchoprovocation with methacholine, adenosine 5'-monophosphate, and allergen in atopic nonasthmatic subjects. Am Rev Respir Dis (1990) 1.01
Leukocyte recruitment after local endobronchial allergen challenge in asthma. Relationship to procedure and to airway interleukin-8 release. Am J Respir Crit Care Med (1996) 1.01
Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol (1988) 1.00
Effects of H1 antagonists on the cutaneous vascular response to histamine and bradykinin: a study using scanning laser Doppler imaging. Br J Dermatol (1998) 1.00
Ragweed sensitization in Europe - GA(2)LEN study suggests increasing prevalence. Allergy (2009) 0.99
Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy (2009) 0.99
The prevalence and distribution of food sensitization in European adults. Allergy (2013) 0.98
Personalized pollen-related symptom-forecast information services for allergic rhinitis patients in Europe. Allergy (2013) 0.98
Correlation of anaphylactic bronchoconstriction with circulating reaginic antibody level and active cutaneous anaphylaxis in the rat. Immunology (1975) 0.98
Allergic eye disease mechanisms. Br J Ophthalmol (1998) 0.98
Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy (2009) 0.98
Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy (2008) 0.97
The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol (1983) 0.97
Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy (2010) 0.97